WGSWW SEC Filings - GeneDx Holdings Corp 10-K, 10-Q, 8-K Forms
This page provides access to GeneDx Holdings SEC filings (WGSWW), including 10-K, 10-Q, 8-K, and insider trading forms. Each filing includes AI-powered summaries to help investors understand key points regarding warrant terms, governance changes, and compensation policies. The platform ensures real-time updates from the SEC’s EDGAR system, making it a comprehensive resource for regulatory disclosures and corporate events.
GeneDx (WGS) CFO exercises 16,250 RSUs, sells shares for taxes
GeneDx Holdings Corp.'s CFO, Kevin Feeley, exercised 16,250 restricted stock units (RSUs) and subsequently sold 8,818 Class A Common Stock shares. These sales, conducted at weighted average prices between $60s and $65s per share, were explicitly for covering tax withholding obligations associated with the RSU vesting, categorized as a "sell to cover" transaction rather than a discretionary trade. Following these transactions, Feeley beneficially owns 34,580 Class A Common Stock shares, with additional contingent rights to 93,173 RSU shares and options for 25,906 shares.
GeneDx (WGS) CEO exercises 80K RSUs, sells 47K shares for taxes
GeneDx Holdings Corp. CEO Katherine Stueland exercised 80,000 restricted stock units (RSUs) and subsequently sold 46,933 shares to cover tax withholding obligations. These "sell to cover" transactions were non-discretionary and executed at weighted average prices between $60.93 and $65.61 per share. After these transactions, the CEO beneficially owns 91,514 shares of Class A common stock, along with additional RSUs and stock options.
GeneDx holdings CFO Feeley sells $557k in shares
GeneDx Holdings CFO Kevin Feeley sold 7,718 shares of Class A Common Stock for approximately $557,051 on March 26, 2026, though he also acquired 16,250 shares through restricted stock unit exercises at $0. This comes as the stock has fallen 17% in the past week, yet analysts maintain Buy ratings with high price targets due to strong Q4 revenue and positive growth outlook, despite new competition.
Can GeneDx (WGS) Turn Cost-Saving Genomics Into Durable Reimbursement Strength?
GeneDx Holdings is gaining positive analyst attention after data presented at the ACMG Annual Meeting showed its genomic tests can reduce healthcare costs and resource use, particularly appealing to payers. While this strengthens the company's case for reimbursement expansion, investors need to be aware of potential risks related to shifts in reimbursement policies or pricing pressures that could impact future value capture despite a recent $100 million term loan from Blackstone. The company projects significant revenue and earnings growth by 2028, leading to a substantial upside in its fair value estimates.
GeneDx Holdings Corp. CEO Katherine Stueland Sells Shares to Cover Tax Obligations
GeneDx Holdings Corp. CEO Katherine Stueland sold 17,179 shares of Class A Common Stock on March 16, 2026, to cover tax withholding obligations from RSU vesting. The sales totaled $1,319,290 at weighted average prices between $76.3492 and $77.9354. Following these transactions, Ms. Stueland directly owns 58,447 shares in the company.
GeneDx (WGS) CEO exercises RSUs, sells 17,179 shares to cover taxes
GeneDx Holdings Corp.'s CEO, Katherine Stueland, exercised restricted stock units (RSUs) covering 30,671 shares. To cover tax withholding obligations from these vestings, she sold 17,179 shares in non-discretionary open-market transactions at prices ranging from $75.74 to $78.16 per share. Following these transactions, she still directly owned 58,447 shares and held RSUs and options for a substantial number of additional shares.
GeneDx (WGS) CFO sells shares to cover RSU tax obligations
GeneDx Holdings Corp.'s CFO, Kevin Feeley, reported exercising restricted stock units (RSUs) obtaining 11,012 shares and subsequently selling 5,706 shares of Class A Common Stock. These sales were non-discretionary and exclusively for covering tax withholding obligations associated with the RSU vesting. Following these transactions, Feeley beneficially owns 27,148 shares of Class A Common Stock, with additional RSUs and options outstanding.
GeneDx CEO Stueland sells $1.32 million in WGS stock
GeneDx Holdings Corp CEO Katherine Stueland sold 17,179 shares of Class A Common Stock for approximately $1.32 million to cover tax withholding obligations. This sale was not a discretionary transaction. Stueland also exercised options for 30,671 shares and continues to hold a significant number of shares, RSUs, and options. The stock is currently trading down, but analysts remain optimistic with price targets ranging from $130 to $177.
GeneDx (WGS) CEO exercises RSUs, sells shares only to cover taxes
GeneDx Holdings Corp. CEO Katherine Stueland exercised restricted stock units (RSUs) into 6,546 shares of Class A Common Stock. She then sold 3,678 of these shares at a weighted average price of $86.748 per share, explicitly stating this was a "sell to cover" transaction to meet tax withholding obligations and not a discretionary sale. Following these transactions, Stueland directly holds 44,955 shares of Class A Common Stock and retains unvested awards of 445,366 RSUs and options for 107,610 shares, which vest over time.
GeneDx Holdings (WGS) CFO exercises RSUs and sells shares to cover taxes
GeneDx Holdings Corp. CFO Kevin Feeley exercised restricted stock units (RSUs) for 2,462 shares and subsequently sold 1,280 shares at a weighted average price of $86.754 to cover tax withholding obligations. This "sell to cover" transaction was not a discretionary trade. After these transactions, Feeley directly holds 21,842 shares of Class A common stock and retains RSUs for an additional 120,435 shares and options for 25,906 shares.
GeneDx (WGS) CFO Kevin Feeley acquires 1,986 shares from issuer
GeneDx Holdings Corp. CFO Kevin Feeley acquired 1,986 shares of Class A common stock directly from the company on March 6, 2026, at a price of $88.11 per share. This transaction was exempt under Rule 16b-3(d) and increased his direct ownership to 20,660 shares. The acquisition was not an open-market purchase but an internal company transaction.
GeneDx CFO Feeley sells $486k in shares By Investing.com
GeneDx CFO Kevin Feeley sold 6,187 shares of Class A Common Stock for approximately $486,370 to cover tax obligations related to a restricted stock unit award. Despite the stock trading down 37% year-to-date, analysts maintain Buy ratings with price targets significantly above current levels. The company recently reported mixed Q4 results, with revenue exceeding expectations but earnings missing, and anticipates 25% to 27% growth for fiscal 2026.
GeneDx (WGS) CFO nets PRSU awards, sells 6,187 shares
GeneDx Holdings Corp.'s CFO, Kevin Feeley, reported acquiring 15,262 Class A Common Stock shares and 10,865 RSUs on March 3, 2026, stemming from a performance-based restricted stock unit award. The next day, he sold 6,187 shares of Class A Common Stock at weighted average prices in the high-$70 range to cover tax withholding obligations related to the vesting of these awards. Following these transactions, Feeley beneficially owns 18,674 shares, along with RSUs for up to 122,897 shares and options for up to 25,906 shares, all subject to further vesting.
GeneDx Holdings (NASDAQ: WGS) CEO acquires 3,404 new shares from company
GeneDx Holdings' CEO, Katherine Stueland, acquired 3,404 shares of the company's Class A common stock on March 6, 2026. The transaction, valued at $88.11 per share, was directly from the company as an exempt transaction under Rule 16b-3(d). Following this acquisition, Ms. Stueland directly holds a total of 42,087 shares.
Free cash flow per share of GeneDx Holdings Corp. Class A – BX:WGS
This article displays the free cash flow per share for GeneDx Holdings Corp. Class A (BX:WGS). It presents financial data for the company on the BX Swiss exchange through TradingView. The content primarily shows the company's name, stock ticker, exchange, and a placeholder for financial values over different periods.
GeneDx CFO Feeley sells $486k in shares
GeneDx CFO Kevin Feeley sold 6,187 shares of Class A Common Stock for $486,370 to cover tax withholding obligations. This sale occurred on March 4, 2026, following an acquisition of 15,262 shares of Class A Common Stock and 10,865 Restricted Stock Units on March 3. The company recently reported mixed Q4 results, with revenue exceeding expectations but earnings falling short, leading analysts to adjust price targets while maintaining buy ratings.
Corvex management buys GeneDx (WGS) shares worth $13.4 million
Corvex Management LP and director Keith A. Meister have purchased approximately $13.4 million worth of GeneDx Holdings Corp. (NASDAQ:WGS) shares on March 3 and March 5, 2026. This insider buying occurred while the stock has seen a 38% decline over the past six months, despite analysts maintaining optimistic price targets ranging from $130 to $177. Recent Q4 results showed GeneDx exceeding revenue expectations but missing on earnings, leading to mixed sentiment and some analyst price target adjustments while ratings largely remained "Buy."
Corvex management buys GeneDx (WGS) shares worth $13.4 million By Investing.com
Corvex Management LP and director Keith A. Meister have purchased approximately $13.4 million worth of GeneDx Holdings Corp. (NASDAQ:WGS) Class A Common Stock across transactions on March 3 and March 5, 2026. This insider buying occurs despite a recent 38% stock decline over six months, with analysts maintaining optimistic price targets ranging from $130 to $177. GeneDx recently reported mixed Q4 2025 results, exceeding revenue expectations but missing earnings.
Corvex management buys GeneDx (WGS) shares worth $13.4 million
Corvex Management LP, including director Keith A. Meister, recently purchased $13.4 million worth of GeneDx Holdings Corp. (NASDAQ:WGS) shares despite a 38% stock decline over the past six months. Analysts, however, maintain an optimistic outlook with price targets ranging from $130 to $177. These purchases occurred on March 3 and March 5, 2026, amid mixed Q4 results for GeneDx, where revenue slightly exceeded expectations but earnings fell short.
GeneDx CFO Feeley sells $486k in shares
GeneDx CFO Kevin Feeley sold 6,187 shares of Class A Common Stock for $486,370 on March 4, 2026, to cover tax obligations. Despite the stock being down 37% year-to-date, analysts maintain price targets significantly above current levels. GeneDx recently reported robust Q4 revenue growth, though it missed earnings expectations, with several firms reiterating "Buy" ratings.
GeneDx CFO Feeley sells $486k in shares
GeneDx Holdings Corp (NASDAQ: WGS) CFO Kevin Feeley sold 6,187 shares of Class A Common Stock for approximately $486,370 on March 4, 2026, to cover tax obligations. Despite the stock being down 37% year-to-date and appearing slightly overvalued, analysts have price targets ranging from $130 to $177, indicating significant upside. The company recently reported mixed Q4 results, exceeding revenue expectations but missing earnings.
EBIT per share of GeneDx Holdings Corp. Class A – BX:WGS
The article displays the EBIT per share for GeneDx Holdings Corp. Class A (BX:WGS) on TradingView. It shows that the data is for a specific period, with values for "Value", "Change", and "Change %" metrics. The article primarily functions as a data display page for financial metrics of the company.
Tax-driven stock sale by GeneDx (WGS) CFO after RSU vest
GeneDx Holdings Corp. CFO Kevin Feeley reported the vesting of 718 restricted stock units (RSUs) on March 1, 2026, which converted into Class A common stock for no cost. On March 2, 2026, Feeley sold 287 of these Class A shares at a weighted average price of $77.5187 per share. This sale was explicitly to cover tax withholding obligations associated with the RSU vesting rather than a discretionary transaction, as detailed in the SEC Form 4 filing.
HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating potential breaches of fiduciary duties by officers and directors of GeneDx Holdings Corp. The firm encourages long-term GeneDx shareholders to contact them to discuss their legal rights, which may include seeking corporate governance reforms or financial returns to the company. Halper Sadeh LLC operates on a contingent fee basis, meaning shareholders would not face out-of-pocket legal fees.
GeneDx Holdings Corp. Class A Common Stock (WGS) Stock Price Today & Analysis
This article provides an analysis of GeneDx Holdings Corp. Class A Common Stock (WGS), including its current stock price, fundamental financials, and company overview. It highlights GeneDx's role in delivering personalized health insights through genomic testing and explains how investors can buy WGS stock through the Gotrade app. The piece also addresses common investor questions like minimum investment, dividend policy, safety, and market hours.
WGS - GeneDx Holdings Corp Latest Stock News & Market Updates
This page provides the latest news and market updates for GeneDx Holdings Corp. (WGS), focusing on their financial performance, scientific advancements in rare disease genomics, and corporate developments. The company frequently issues updates on financial results, clinical milestones, leadership changes, and strategic partnerships, leveraging its GeneDx Infinity dataset to advance genomic medicine. Recent news includes their Q4 and full-year 2022 financial results, participation in healthcare conferences, and successful public offerings.
These Analysts Slash Their Forecasts On GeneDx After Q4 Results
Following its Q4 results, GeneDx Holdings Corp. (NASDAQ: WGS) beat analyst estimates for both earnings and sales, with a reported 14 cents per share and $120.989 million, respectively. Despite the better-than-expected performance and affirmed FY2026 sales guidance, the company's shares fell 6.1%, prompting analysts from BTIG and Piper Sandler to lower their price targets on WGS. GeneDx's CEO highlighted the company's strong position and growth drivers in genomic diagnosis.
GeneDx (NASDAQ: WGS) outlines genomic testing growth strategy
GeneDx (NASDAQ: WGS) has detailed its growth strategy for genomic testing, emphasizing its exome and whole genome sequencing for rare pediatric disorders, which hold FDA Breakthrough Device Designation. The company plans to expand its market-leading tests into pediatric outpatient settings, NICUs, and internationally through its recent acquisition of Fabric Genomics. This strategy leverages GeneDx Infinity™, one of the world's largest rare disease datasets, enhanced by AI tools for faster and more accurate diagnoses.
GeneDx Holdings Corp. (WGS) Surged Following Strong Earnings and Improved Guidance
Polen Capital's "Polen 5Perspectives Small Growth Strategy" highlighted GeneDx Holdings Corp. (NASDAQ:WGS) in its Q4 2025 investor letter, noting the genomics company's strong performance. GeneDx delivered better-than-expected results, including raised full-year guidance, driven by increased genetic testing volumes and improved insurance reimbursement rates. The company, which specializes in diagnosing rare genetic disorders, saw its stock close at $87.08 per share on February 23, 2026, with 39 hedge funds holding its shares by the end of Q4 2025.
GeneDx Holdings Q4 Earnings Report: What Investors Need to Know
GeneDx Holdings (NASDAQ: WGS) reported its Q4 earnings, beating estimated EPS by 16.67% with an EPS of $0.14 against an estimate of $0.12. Revenue for the quarter also increased by $25.35 million year-over-year. Despite beating EPS in the previous quarter, the company saw a 4.15% drop in share price the following day.
A Preview Of GeneDx Hldgs's Earnings
GeneDx Holdings Corp. (NASDAQ: WGS) is set to release its quarterly earnings report on Monday, February 23, 2026. Analysts project an EPS of $0.12 for the company. The article provides a summary of past earnings performance, stock price changes, and current stock performance, noting an 8.06% decline in shares over the last 52 weeks.
GeneDx COO Dechairo sells $510k in WGS stock By Investing.com
GeneDx Holdings Corp.'s COO, Bryan Dechairo, sold 6,061 shares of Class A Common Stock for over $510,000 on February 4, 2026, as part of a pre-arranged trading plan. This transaction leaves him with zero direct shares, occurring amidst recent stock volatility. Despite the sales, analysts maintain optimistic price targets for GeneDx, which projects significant revenue growth for 2026 and has announced new strategic partnerships and product launches.
GeneDx COO Dechairo sells $510k in WGS stock
GeneDx Holdings Corp. COO Bryan Dechairo sold 6,061 shares of Class A Common Stock for over $510,000 on February 4, 2026, as part of a pre-arranged trading plan, leaving him with no direct ownership. Despite a recent stock decline, analysts remain optimistic about WGS, with price targets ranging from $153 to $200. The company anticipates strong revenue growth for 2025 and 2026, is launching a new prenatal test, and has appointed a new Chief Medical Officer.
WGS (WGS) investor files Form 144 to sell 9,374 Class A shares
A holder of GeneDx Holdings Corp. (WGS) Class A common stock has filed a Form 144 to sell 9,374 shares. These shares, with an aggregate market value of $929,900, were acquired as compensation in January 2025 and are intended to be sold on NASDAQ around February 2, 2026, through Morgan Stanley Smith Barney. The filing indicates a neutral impact and sentiment regarding the sale relative to the total outstanding shares.
Surging AI-Driven Genetic Testing Demand Might Change The Case For Investing In GeneDx Holdings (WGS)
GeneDx Holdings (WGS) recently reported strong revenue growth of 51.90%, driven by increasing demand for its AI-powered genetic testing services focused on pediatric and rare disease diagnostics. While this growth and FDA Breakthrough status strengthen its investment thesis, significant share price pullback, high sales multiples, and insider selling introduce execution and valuation risks. Despite the optimism, investors hold widely divergent fair value estimates, emphasizing the importance of comprehensive research beyond the headlines.
GeneDx Holdings Corp. (NASDAQ:WGS) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
GeneDx Holdings Corp.'s shares dropped 29% over the past month, though the stock still shows a 34% gain over the last year. Despite the recent dip, the company maintains a high price-to-sales ratio of 7.2x, significantly above the industry average, driven by strong revenue growth of 51% last year and a forecast of 22% annual growth for the next three years. This anticipated strong performance relative to the Healthcare industry's 6.1% growth appears to be sustaining investor confidence and the elevated P/S ratio.
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. The firm encourages long-term GeneDx shareholders to contact them to explore legal options such as seeking corporate governance reforms, fund recovery, or financial incentives. Halper Sadeh LLC handles actions on a contingent fee basis, and shareholder participation is highlighted as important for improving company policies and enhancing shareholder value.
A Look At GeneDx Holdings (WGS) Valuation After GenomeDx Prenatal Launch And New Chief Medical Officer Appointment
GeneDx Holdings (WGS) has launched GenomeDx Prenatal, a new whole genome sequencing test, and appointed Dr. Linda Genen as Chief Medical Officer. Despite recent stock fluctuations, the company shows strong long-term momentum, trading at a significant discount to analyst price targets and estimated fair value. The article explores the valuation gap and potential factors influencing its future growth and profitability, highlighting both opportunities and challenges.
Should GeneDx’s GUARDIAN Newborn Genomics Accolade Reshape the Investment Narrative for WGS Investors?
GeneDx Holdings Corp. (WGS) received significant recognition for its GUARDIAN newborn genomic screening work, being selected among JAMA’s Research of the Year. This accolade strengthens the investment narrative around broader pediatric and NICU adoption of its genomics platform, however, the company still faces risks related to payer reimbursement and cost containment. GeneDx's narrative projects substantial revenue and earnings growth by 2028, with Simply Wall St's fair value estimate suggesting a 25% upside from its current price.
Is JAMA’s GUARDIAN Nod Quietly Reframing GeneDx (WGS) as a Core Newborn Genomics Platform?
JAMA's recognition of GeneDx's GUARDIAN study highlights the potential of large-scale genomic newborn screening to detect treatable, often-missed childhood conditions and strengthens the clinical case for widespread adoption. While this bolsters GeneDx's investment narrative, the company's long-term success still hinges on broader payer and health system adoption, as well as managing reimbursement and pricing pressures. The FDA Breakthrough Device Designation also supports their efforts to build regulatory-grade evidence for future policy decisions and hospital integration.
News Headline | Today! The Largest Options Expiry in History: Will U.S. Stocks Face a "Wild Day"?
Wall Street is bracing for an unprecedented "triple witching" event with a record-breaking $7.1 trillion in options contracts set to expire, including $5 trillion linked to the S&P 500 Index. This historic expiry could lead to significant market volatility or a "pinning" effect, with analysts closely watching the S&P 500's ability to hold the critical 6,800-point level. The massive volume and potential for dramatic market swings make this a crucial event for year-end market movements.
GeneDx (WGS) Valuation Check as JAMA Highlights GUARDIAN Newborn Genomic Screening Study
GeneDx Holdings (WGS) has seen a significant boost with its GUARDIAN newborn genomic screening study being highlighted in JAMA’s Research of the Year, leading to a 76% year-to-date share price increase. While analysts estimate its fair value in the mid-$160s, suggesting it's undervalued, a Simply Wall St DCF model is even more optimistic, valuing shares around $253.46. Investors are evaluating whether the market is underestimating GeneDx's long-term potential in newborn genomics.
GeneDx Holdings Corp. Executives Sell Shares for Tax Obligations
GeneDx Holdings Corp.'s CEO, Katherine Stueland, and CFO, Kevin Feeley, sold shares to cover tax obligations related to RSU vesting. Stueland sold 10,857 shares for $1,562,185, and Feeley sold 3,855 shares for $554,616. Following these transactions on December 16, 2025, Stueland directly owns 14,237 shares and Feeley directly owns 8,731 shares.
GeneDx Holdings Corp. Executives Sell Shares to Cover Tax Obligations
GeneDx Holdings Corp.'s CEO, Katherine Stueland, and CFO, Kevin Feeley, recently sold shares of Class A Common Stock to cover tax obligations from vested restricted stock units (RSUs). Stueland sold 3,639 shares for $579,619, while Feeley sold 1,266 shares for $201,648, both on December 9, 2025, at $159.28 per share. These sales were solely for tax withholding purposes.
Feeley, GeneDx CFO, sells $61,276 in WGS stock
GeneDx Holdings Corp CFO Kevin Feeley sold 377 shares of Class A Common Stock for $61,276 on December 1, 2025, while also exercising options on 717 shares. This news follows recent Q3 2025 earnings where GeneDx missed EPS expectations but exceeded revenue forecasts and raised its 2025 guidance. Analysts from Guggenheim and BTIG subsequently increased their price targets for GeneDx, maintaining Buy ratings due to strong growth in genetic testing.
HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of GeneDx stock to contact them to learn about potential legal rights and options, including seeking corporate governance reforms or financial incentives. Halper Sadeh LLC handles these actions on a contingent fee basis.
GeneDx (WGS) Valuation After New Clinical Breakthroughs Spotlighted Ahead of 2025 NSGC Conference
GeneDx Holdings is gaining attention for its upcoming presentations at the 2025 National Society of Genetic Counselors Annual Meeting, focusing on advancements in rare disease diagnosis. The company's stock has seen significant growth, with a 14.9% 1-month share price return and an 81.9% total shareholder return over the past year, prompting discussions about its valuation. While narratives suggest a 7.5% undervaluation, a DCF model indicates shares might be trading 44.8% below fair value.
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
GeneDx announced strong third-quarter 2025 financial results, with significant revenue and exome/genome test volume growth. The company raised its full-year 2025 guidance and highlighted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests, along with its leading role in genomic newborn screening initiatives like BEACONS and the Sunshine Genetics Network. These achievements underscore GeneDx's focus on advancing precision medicine and improving health outcomes through genomic insights.
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims
Schubert Jonckheer & Kolbe LLP is investigating GeneDx Holdings Corp. (NASDAQ: WGS) for potential legal claims related to allegations that the company misled investors about its health intelligence platform, Centrellis. A U.S. District Judge has allowed a securities fraud lawsuit to proceed, alleging GeneDx overstated Centris's capabilities and commercial viability, leading to artificially inflated stock prices. The firm encourages current shareholders of GeneDx to contact them regarding possible legal options.
